Creative Medical Technology Holdings, Inc.

NCM: CELZ

Live Quote

📈 ZcoreAI Score

Our AI model analyzes Creative Medical Technology Holdings, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.

Get CELZ Z-Score →

About Creative Medical Technology Holdings, Inc.

Healthcare Biotechnology

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

📊 Fundamental Analysis

Creative Medical Technology Holdings, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.

The company recently reported 0.0% revenue growth, which is negative, indicating a recent decline in revenue.

Return on Equity (ROE) is -86.5%, which indicates that capital utilization is currently under pressure.

At a current price of $2.14, CELZ currently trades near the bottom of its 52-week range (13%), indicating potential value or weakness (Range: $1.50 - $6.25).

🏥 Financial Health

🔴 Profit Margin Weak

✅ Debt/Equity Excellent

🔴 Revenue Growth Weak

🔴 Return on Equity Weak

🔴 Beta (Risk) High Volatility

Key Financials

Market Cap

$7.91M

Trailing P/E

Forward P/E

-1.59

Beta (5Y)

1.99

52W High

$6.25

52W Low

$1.50

Avg Volume

50K

Day High

Day Low

Get CELZ Z-Score on Dashboard 🚀